Aflibercept monotherapy or bevacizumab first for diabetic macular edema
Jhaveri CD, Glassman AR, Ferris FL, et al.
N Engl J Med. 2022 Jul 14
Leggi
Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity
Gupta J, Antal Z, Mauer E, et al.
BMC Endocr Disord. 2022 Jul 16;22(1):180
Leggi
Outcomes after acute coronary syndrome in patients with diabetes mellitus and peripheral artery disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO clinical trials)
Attar R, Wu A, Wojdyla D, et al.
Am J Cardiol. 2022;S0002-9149(22)00579-3
Leggi
Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study
Manisha AM, Shangali AR, Mfinanga SG, Mbugi EV
BMC Endocrine Disorders. 2022;22(1):175
Leggi
Health care organization and use of technological devices in people with diabetes in Italy: Result from a survey of the working group on diabetes and technology
Pitocco D, Laurenzi A, Tomaselli L, et al.
NMCD. Published online, 14 July 2022
Leggi
Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: perspective based on the updated evidence
Khunti K, Aroda VR, Bhatt DL, et al.
Diabetes Obes Metab. 2022, Jul 8
Leggi
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Zou X, Huang Q, Luo Y
Diabetologia. 2022 Jul 8. Online ahead of print
Leggi
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials
Leite AR, Angélico-Gonçalves A, Vasques-Nóvoa F, et al
Diabetes Obes Metab. 2022 Aug;24(8):1676-1680
Leggi
FAD AMD – DIABETE E SCOMPENSO CARDIACO
Vi invitiamo a seguire questo nuovo percorso formativo dedicato ad un approfondimento in materia di diabete e scompenso cardiaco. Scopo dell’iniziativa è quello di acquisire capacità di diagnosi dello scompenso ed approfondire l’utilizzo dei farmaci innovativi (SGLT2i) al fine di ridurre il rischio di ricovero nelle persone con diabete tipo…
Leggi